
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics is expected to achieve significant milestones and data in its ongoing clinical trials, which could serve as strong catalysts for the company's stock. With no revenue, the company's main product candidate, (Z)-endoxifen, is being evaluated for the treatment and prevention of breast cancer and other indications, with plans to enter the metastatic breast cancer market. Despite risks such as liquidity and regulatory approvals, Ascendiant Capital Markets has maintained a BUY rating for the company with a target price of $8.00, based on its strong growth prospects and significant upside potential.
Bears say
Atossa Therapeutics is making steady progress on its clinical trials and is actively cooperating with the FDA to explore additional indications for its lead product candidate, (Z)-endoxifen. However, the company's drugs are still in the early stages of development, making them highly risky investments. Despite the potential billion dollar market for Atossa's products, the potential for clinical trial failures remains a significant concern, making a negative outlook on the stock justifiable.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares